Corient Private Wealth
IBRX icon

Corient Private Wealth’s ImmunityBio IBRX Stock Holding History

Corient Private Wealth’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.6M Sell
182,713
-22,332
-11% -$169K ﹤0.01% 1527
2026
Q1 		$1.55M Buy
205,045
+18,670
+10% +$128K ﹤0.01% 1404
2025
Q4 		$369K Sell
186,375
-9,916
-5% -$22.5K ﹤0.01% 2038
2025
Q3 		$483K Sell
196,291
-9,304
-5% -$24K ﹤0.01% 1809
2025
Q2 		$543K Sell
205,595
-22,073
-10% -$59.4K ﹤0.01% 1664
2025
Q1 		$685K Buy
227,668
+5,288
+2% +$16K ﹤0.01% 1450
2024
Q4 		$569K Sell
222,380
-224,080
-50% -$933K ﹤0.01% 1548
2024
Q3 		$1.66M Buy
446,460
+224,380
+101% +$1.04M ﹤0.01% 1180
2024
Q2 		$1.4M Buy
222,080
+550
+0.2% +$3.63K ﹤0.01% 1189
2024
Q1 		$1.19M Sell
221,530
-1,900
-0.9% -$8.6K ﹤0.01% 1252
2023
Q4 		$1.12M Buy
223,430
+49,729
+29% +$156K ﹤0.01% 1238
2023
Q3 		$294K Buy
173,701
+114,272
+192% +$229K ﹤0.01% 1755
2023
Q2 		$165K Sell
59,429
-53
-0.1% -$150 ﹤0.01% 1909
2023
Q1 		$108K Buy
59,482
+35,852
+152% +$111K ﹤0.01% 1873
2022
Q4 		$120K Buy
+23,630
New +$130K ﹤0.01% 1547

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Corient Private Wealth's IBRX Position: Q2 2026 in Review

Corient Private Wealth reduced its ImmunityBio (IBRX) stake by 11% in Q2 2026, selling an estimated $169K and leaving 182,713 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1527.

Corient Private Wealth first reported a position in IBRX in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.66M in Q3 2024. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Corient Private Wealth held 182,713 shares of ImmunityBio worth $1.6M as of Q2 2026.
  • Corient Private Wealth sold 22,332 ImmunityBio shares in Q2 2026, an estimated $169K.
  • ImmunityBio made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1527 holding.
  • Corient Private Wealth first reported a position in ImmunityBio in Q4 2022 and has held it in 15 quarters since.
  • Corient Private Wealth's ImmunityBio position peaked at $1.66M in Q3 2024.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.